Cargando…
A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab
Autores principales: | Bonomi, Lucia, Ghilardi, Laura, Arnoldi, Ermenegildo, Tondini, Carlo Alberto, Bettini, Anna Cecilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Association for the Study of Lung Cancer. Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270552/ https://www.ncbi.nlm.nih.gov/pubmed/32243919 http://dx.doi.org/10.1016/j.jtho.2020.03.021 |
Ejemplares similares
-
Prevalence and Clinical Impact of SARS‐CoV‐2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID‐19 Pandemic
por: Zambelli, Alberto, et al.
Publicado: (2021) -
Nivolumab‐induced fatal myocarditis: A case report
por: Bharathidasan, Kavya, et al.
Publicado: (2023) -
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018) -
Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic
por: Souza, Ive L., et al.
Publicado: (2020) -
A Case of Nivolumab-Induced Myositis
por: Fox, Eric, et al.
Publicado: (2016)